Novo Nordisk's Buyback Runs Ahead of Its Earnings Story as Ozempic Pressure Mounts
Published on 10/26/2026 at 12:50 | Editorial boerse-global.de
Novo Nordisk has spent the past several weeks stacking up announcements — a pediatric label for its weekly insulin, a fresh look at CagriSema data, and a steady drip of share repurchases. None of them, on their own, answers the question that matters most to investors right now: how much revenue Ozempic can still deliver.
That gap between medical headlines and commercial reality is exactly where BMO Capital's Evan Seigerman staked his position on 12 October. According to media reports, he trimmed his price target to $40 from $47 while keeping a "Market Perform" rating on the stock. His concern centers on Ozempic specifically — a tough comparative quarter and eroding US market share, both of which could weigh on sales of the diabetes drug.
A Capital Return Program, Not a Growth Signal
Separately, Novo Nordisk's mandatory disclosure filed on 19 October shows the company is working through an existing buyback authorization rather than launching anything new. The program permits up to DKK 15 billion in repurchases over twelve months starting 4 February 2026 — a ceiling, not a completed transaction.
The distinction matters. An authorization and its actual use are two different things, and the filing simply documents progress without announcing any expansion. As of 16 October, Novo Nordisk had bought back 39,074,179 B shares for a total of DKK 10,875,024,304, per the notice lodged with the US securities regulator.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That is a concrete capital measure sitting alongside the product news. Its informational value has limits, though: the documented share purchases say nothing about how revenue and earnings are developing.
What the Pipeline Delivered
On the medical side, the FDA approved Awiqli as a once-weekly basal insulin for children aged ten and older with type 2 diabetes, aimed at improving blood sugar control. By the company's account, it is the first and only weekly insulin option for this patient group. The approval is a genuine regulatory step forward, but its immediate relevance is confined to Awiqli's cleared indication — it does not address the US share losses Seigerman flagged for Ozempic.
Roughly a week earlier, Novo Nordisk presented post-hoc analyses from the REDEFINE 1 trial. Among 2,309 women with overweight or obesity, the investigational CagriSema produced an average weight reduction of 25.0% after 68 weeks, compared with 3% on placebo. The findings were presented at the annual meeting of the Menopause Society.
Two caveats belong with those numbers. The analysis assumed continued treatment adherence, and it is a retrospective look at a specific subgroup rather than a regulatory decision. Read the data as a clinical finding, not as business success already banked.
The Date That Ties It Together
Novo Nordisk has scheduled its results for the first nine months of the year on 4 November 2026. That report will put hard figures alongside both the product announcements and the buyback tally.
Until then, the line to hold is straightforward. Approvals and trial data document medical progress; buybacks document how capital is being deployed. Whether either offsets the commercial pressure on Ozempic has to be measured against actual business performance — and that scorecard arrives in November.
Ad
Novo Nordisk Stock: New Analysis - 26 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
